IFRX
InflaRx N.V. Common Stock
stockNASDAQ
inflarx n.v., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using c5a technology primarily in the germany and united states. its c5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. the company's lead product candidate is ifx-1, an intravenously delivered first-in-class anti-c5a monoclonal antibody, which completed the phase iib clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat anca-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing ifx-1 for the treatment of oncological diseases. it also develops ifx-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. inflarx n.v. has co-development agreement with beijing defe
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.82 | 2026-09-28 | -5.50% | 0.880 |
| 1M | 2.22 | 2026-09-04 | -22.52% | 1.977 |
| 3M | 2.11 | 2026-07-06 | -18.48% | 1.551 |
| 6M | 0.94 | 2026-04-06 | +82.32% | 1.867 |
| 1Y | 1.58 | 2025-10-03 | +8.86% | 2.290 |
| 2Y | 1.56 | 2024-10-04 | +10.26% | — |
| 5Y | 2.45 | 2021-10-04 | -29.80% | 0.849 |
InflaRx N.V. Common Stock (NASDAQ:IFRX) stock price today is $1.72, and today's volume is 422,162. IFRX is up 0.585% today. The 30 day average volume is 671,060. IFRX market cap is $253.47M with 147.37M shares outstanding.